Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Metabolic and Endocrine Disorders

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 3 · 100%

Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 592 participants
High

Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1103 participants
High

Change in body weight from baseline to endpoint ‐ Sitagliptin versus placebo kg ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1109 participants
High